

D-A046 966

TEXAS UNIV HEALTH SCIENCE CENTER AT DALLAS

F/G 6/1

WATER-SOLUBLE MACROMOLECULAR COMPLEXES OF KALLIKREIN, BRADYKINI--ETC(U)

NOV 77 C E ODYA, Y LEVIN, E G ERDOS

N00014-75-C-0807

UNCLASSIFIED

TR-10

NL

| OF |
AD
A046 966



END
DATE
FILMED
12-77
DDC

AD A 0 4 6 9 6 6

12

OFFICE OF NAVAL RESEARCH

Contract N00014-75-C-0807

TECHNICAL REPORT NO. 10

Water-Soluble Macromolecular Complexes of Kallikrein,
Bradykinin and Inhibitors of Kallikrein and Kininase II

Prepared by

Ervin G. Erdős

For Publication in
Kininogenases

Departments of Pharmacology and Internal Medicine
University of Texas Health Science Center at Dallas
5323 Harry Hines Boulevard
Dallas, Texas 75235

04 November 1977

Reproduction in whole or in part is permitted for
any purpose of the United States Government

Distribution of this report is unlimited



AD No. —
DDC FILE COPY

REPORT DOCUMENTATION PAGE		READ INSTRUCTIONS BEFORE COMPLETING FORM
1. REPORT NUMBER Technical Report 10 ✓	2. GOVT ACCESSION NO.	3. RECIPIENT'S CATALOG NUMBER
4. TITLE (and Subtitle) ⑥ WATER-SOLUBLE MACROMOLECULAR COMPLEXES OF KALLIKREIN, BRADYKININ AND INHIBITORS OF KALLIKREIN AND KININASE II.		5. TYPE OF REPORT & PERIOD COVERED Technical 6/1/77 - 12/15/78
7. AUTHOR(s) ⑩ C. E. Ody, Y. Levin, E. G. Ervin, G. Erdős		6. PERFORMING ORG. REPORT NUMBER
8. PERFORMING ORGANIZATION NAME AND ADDRESS Univ. of TX Health Sci. Center @ Dallas Dept. of Pharmacology 5323 Harry Hines Blvd., Dallas, TX 75235 ✓		9. CONTRACT OR GRANT NUMBER(s) ⑮ NSG 14-75-C-0807 ✓
11. CONTROLLING OFFICE NAME AND ADDRESS Office of Naval Research Biological & Medical Sciences Division Medical and Dental Sciences Program, Code 444 Arlington, VA		10. MONITORING AGENCY NAME & ADDRESS (if different from Controlling Office) ✓ PHS-HL-14187
12. MONITORING AGENCY NAME & ADDRESS (if different from Controlling Office) ⑨ Technical rept. 1 Jun 77 - 15 Dec 78		11. REPORT DATE 11/04/77
13. DISTRIBUTION STATEMENT (of this Report) Distribution of this document is unlimited ⑫ 17p. ⑭ TR-14		12. NUMBER OF PAGES 13
14. DISTRIBUTION STATEMENT (of the abstract entered in Block 20, if different from Report)		13. SECURITY CLASS. (of this report) Unclassified
15. SUPPLEMENTARY NOTES Presented at the spring meeting of FASEB in Chicago, IL. To be published in Kininogenases, G. L. Haberland (ed.) Schattauer, Pbl. Stuttgart.		14. DECLASSIFICATION/DOWNGRADING SCHEDULE
16. KEY WORDS (Continue on reverse side if necessary and identify by block number) Trasylol, kallikrein, angiotensin I converting enzyme, kininase, kinins		
17. ABSTRACT (Continue on reverse side if necessary and identify by block number) ⑰ Pig pancreatic kallikrein, aprotinin (Trasylol), SQ 21541, an angiotensin I converting enzyme or kininase II inhibitor, and bradykinin were each coupled covalently to soluble dextran (m.w. 500,000). Dextran had been activated either with cyanogen bromide or sodium meta-periodate. Of the reactants, 23 to 56% were bound to activated dextran. The activities of the complexes were determined in vitro by spectrophotometric technique or radioimmunoassay and bioassay. Depending on the mode of coupling and the test employed soluble macromolecular complexes retained 6 to 92% of the in vitro activity of the native compound.		

REPORT DOCUMENTATION PAGE

20. ~~Adverse~~

Bradykinin coupled covalently to dextran was inactivated slower by converting enzyme than was free bradykinin.

1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206
2207
2208
2209
2210
2211
2212
2213
2214
2215
2216
2217
2218
2219
2220
2221
2222
2223
2224
2225
2226
2227
2228
2229
2230
2231
2232
2233
2234
2235
2236
2237
2238
2239
2240
2241
2242
2243
2244
2245
2246
2247
2248
2249
2250
2251
2252
2253
2254
2255
2256
2257
2258
2259
2260
2261
2262
2263
2264
2265
2266
2267
2268
2269
2270
2271
2272
2273
2274
2275
2276
2277
2278
2279
2280
2281
2282
2283
2284
2285
2286
2287
2288
2289
2290
2291
2292
2293
2294
2295
2296
2297
2298
2299
2300
2301
2302
2303
2304
2305
2306
2307
2308
2309
2310
2311
2312
2313
2314
2315
2316
2317
2318
2319
2320
2321
2322
2323
2324
2325
2326
2327
2328
2329
2330
2331
2332
2333
2334
2335
2336
2337
2338
2339
2340
2341
2342
2343
2344
2345
2346
2347
2348
2349
2350
2351
2352
2353
2354
2355
2356
2357
2358
2359
2360
2361
2362
2363
2364
2365
2366
2367
2368
2369
2370
2371
2372
2373
2374
2375
2376
2377
2378
2379
2380
2381
2382
2383
2384
2385
2386
2387
2388
2389
2390
2391
2392
2393
2394
2395
2396
2397
2398
2399
2400
2401
2402
2403
2404
2405
2406
2407
2408
2409
2410
2411
2412
2413
2414
2415
2416
2417
2418
2419
2420
2421
2422
2423
2424
2425
2426
2427
2428
2429
2430
2431
2432
2433
2434
2435
2436
2437
2438
2439
2440
2441
2442
2443
2444
2445
2446
2447
2448
2449
2450
2451
2452
2453
2454
2455
2456
2457
2458
2459
2460
2461
2462
2463
2464
2465
2466
2467
2468
2469
2470
2471
2472
2473
2474
2475
2476
2477
2478
2479
2480
2481
2482
2483
2484
2485
2486
2487
2488
2489
2490
2491
2492
2493
2494
2495
2496
2497
2498
2499
2500
2501
2502
2503
2504
2505
2506
2507
2508
2509
2510
2511
2512
2513
2514
2515
2516
2517
2518
2519
2520
2521
2522
2523
2524
2525
2526
2527
2528
2529
2530
2531
2532
2533
2534
2535
2536
2537
2538
2539
2540
2541
2542
2543
2544
2545
2546
2547
2548
2549
2550
2551
2552
2553
2554
2555
2556
2557
2558
2559
2560
2561
2562
2563
2564
2565
2566
2567
2568
2569
2570
2571
2572
2573
2574
2575
2576
2577
2578
2579
2580
2581
2582
2583
2584
2585
2586
2587
2588
2589
2590
2591
2592
2593
2594
2595
2596
2597
2598
2599
2600
2601
2602
2603
2604
2605
2606
2607
2608
2609
2610
2611
2612
2613
2614
26

Office of Naval Research
Physical & Medical Sciences Division
Medical and Dental Sciences Branch, Code
6010

1944

100

INSTRUMENTAL

Handwritten note at the bottom of the page, oriented vertically: "Handwritten note at the bottom of the page, oriented vertically."

THE ABOVE IS A SUMMARY OF THE INFORMATION RECEIVED FROM THE SOURCE.

RECEIVED AT THE OFFICE OF THE SECRETARY OF DEFENSE

to be enrolled in kindergarten. E. J. 1947.

1954


1. The first of these is the fact that the

0-7777

1. The first of these is the fact that the

... ..

1944-1945



SECURITY CLASSIFICATION OF THIS PAGE

**Water-Soluble Macromolecular Complexes of Kallikrein,
Bradykinin and Inhibitors of Kallikrein and Kininase II**

C. E. Ody, Y. Levin, E. G. Erdős

ACCESSION for	
NTIS	<input checked="" type="checkbox"/> NTIS Section
DOC	<input type="checkbox"/> B. H. Section
UNANNOUNCED	<input type="checkbox"/>
JUSTIFICATION	
BY	
DISTRIBUTION/AVAILABILITY	
DATE	FILE
A	

INTRODUCTION

Although proteins and peptides coupled to insoluble materials (1), including kallikreins and their inhibitors (2,3,4) and Hageman factor (5), have been employed frequently in vitro they could not be used in vivo because they are insoluble. The potential therapeutic usefulness of active, soluble dextran complexes of biologically important substances makes it desirable to prepare and evaluate such conjugates. Therefore, we have prepared soluble dextran complexes of kallikrein, aprotinin (Trasylol), SQ 21541, a synthetic hexapeptide inhibitor of kininase II or angiotensin I converting enzyme (6), (peptidyl dipeptidase), and bradykinin.**

MATERIALS AND METHODS

The details of the materials and techniques used were given in our previous publication (7).

Coupling to Cyanogen Bromide Activated Dextran (CNBr-Dextran)

Dextran (500,000 m.w.) was activated with cyanogen bromide according to the method of Axen et al. (8).

Solutions of aprotinin, 1 mg/ml, kallikrein, 5 mg/ml, and bradykinin, 2.5 mg/ml were prepared in 0.1 M sodium phosphate buffer, pH 7.6. One ml of each of these solutions was allowed to react with 4 ml of the CNBr-dextran solution for 60 h at 5°.

The separation of free aprotinin and kallikrein from that bound to dextran was achieved by filtration at 5° and 40 PSI N₂ through an Amicon XM100A membrane. Bradykinin was removed from that coupled to CNBr-dextran by dialysis at 5° against 0.1 M sodium phosphate buffer, pH 7.6, 1 M sodium chloride, and water respectively.

Coupling to Sodium meta-periodate Activated Dextran (SMP-Dextran)

Dextran (500,000 m.w.) was oxidized with sodium meta-periodate.

Solutions of aprotinin, 0.4 mg/ml, kallikrein, 2.0 mg/ml, bradykinin, 1 mg/ml and SQ 21541, 1 mg/ml, were prepared in 0.1 M sodium phosphate buffer, pH 7.6. Equal volumes of oxidized dextran and of compounds to be coupled were allowed to react for either 16 or 60 h at 5°. The reactive groups remaining on the oxidized dextran at the end of the coupling reaction were reduced with borohydride. This step also converts to stable secondary amines, the unstable Schiff bases that are formed when the peptides and proteins react with oxidized dextran.

The uncoupled compounds were separated from those bound as described above for CNBr-dextran.

Analysis of the Dextran Complexes

The amount of protein or peptide coupled to dextran was determined by amino acid analysis with a Beckman Model 121 automatic amino acid analyzer. The amount bound was calculated from known amino acid composition excluding methionine and cysteine. When SMP-dextran was used arginine was also excluded from the calculations.

Assays

Kallikrein activity was measured by following the hydrolysis of 1×10^{-3} M benzoylarginine ethylester (BAEe) by the enzyme at room temperature in a Cary 118 recording spectrophotometer at $\lambda=254$ nm (7). Aprotinin activity was measured by determining its inhibition of the hydrolysis of BAEe by kallikrein. The inhibitor was pre-incubated with the enzyme for 10 min at room temperature. SQ 21541 activity was measured by assaying its inhibition of the hydrolysis of hippuryl-glycyl-glycine (Hip-Gly-Gly; 10^{-3} M) by purified swine kidney angiotensin

I converting enzyme (6).

The biological potencies of bradykinin-dextran complexes were determined on isolated guinea pig ileum and rat uterus preparations (7). The immunological activities of the complexes were assessed in a bradykinin radioimmunoassay that employed ^{125}I -Tyr⁵-bradykinin as the labeled antigen, rabbit antibradykinin serum, and dextran coated charcoal to separate bound from free antigen (9). The bradykinin-dextran complexes were compared to bradykinin as inhibitors of labeled antigen binding.

The hydrolysis of bradykinin or bradykinin-dextran by purified swine kidney converting enzyme was determined in two ways. Bradykinin, $2 \times 10^{-5}\text{M}$, or an equivalent concentration of its dextran complex was incubated with the enzyme for varying lengths of time at 37° and the residual bradykinin measured by radioimmunoassay. Free and dextran bound-bradykinin were also tested as inhibitors of the hydrolysis of Hip-Gly-Gly by converting enzyme (6). Purified swine kidney converting enzyme was equilibrated at 37° for 10 min, then Hip-Gly-Gly (10^{-3}M) was added followed immediately by bradykinin or bradykinin SMP-dextran.

RESULTS

Kallikrein

From the amount of kallikrein allowed to react with CNBr-dextran, 56% had been coupled. Bound kallikrein had 72% of the esterase activity of the native enzyme (Fig. 1; Table 1). The activity of uncoupled kallikrein was 121 U BAEe per mg protein. (One U of enzyme activity equals 1 umole of BAEe cleaved in 1 min.)

Aprotinin (Trasylol)

Thirty-five percent of the aprotinin allowed to react with CNBr-dextran was coupled covalently (4.4 $\mu\text{g}/\text{mg}$). Fig. 2 shows the inhibition of BAEe esterase

Fig. 2
1

activity of purified, uncoupled kallikrein by free and bound aprotinin. When the I_{50} values of the aprotinins were compared, the CNBr-dextran complex had 41% of the activity of the uncoupled inhibitor.(Table 1).

SQ 21541

The mean amount of SQ 21541 bound to SMP-dextran for 4 preparations was 9.1 μ g per mg dextran (SD 0.8). Based on the total amount of SQ 21541 allowed to react in these preparations, 38% (SD 4.4) had been bound. SQ 21541 SMP-dextran was tested as an inhibitor of converting enzyme. Calculated from the I_{50} values of the 4 preparations. SQ 21541 bound to SMP-dextran has 24% (SD 4.0) the inhibitory activity of the uncoupled peptide.(Table 1).

Bradykinin

The amount of bradykinin bound to SMP-dextran in 5 preparations was 10.2 μ g per mg dextran (SD 2.7). Of the total amount of bradykinin allowed to react with dextran, 45% (SD 15) had been bound. The corresponding figures for bradykinin coupled to CNBr-dextran were 7 μ g per mg dextran and 23%.(Table 1).

The relative biological potency (unbound bradykinin = 100%) of bradykinin SMP-dextran was 29% (SD 12) when assayed on the isolated rat uterus and 18% (SD 8) when assayed on the isolated guinea pig ileum. The bradykinin CNBr-dextran complex had only 6% (SD 6) the biological potency of bradykinin on the rat uterus.

The relative immunological activities of the bradykinin dextran complexes were determined by radioimmunoassay. Estimates of the relative immunological activities (bradykinin = 100%) were made by comparing the concentrations that yielded 50% inhibition of the binding of $^{125}\text{I-Tyr}^5$ bradykinin to the antiserum. The relative immunological activity of the bradykinin SMP-dextran was 80% (SD 17) while that of bradykinin CNBr-dextran was 92% (SD 30).

The hydrolysis of bradykinin and bradykinin bound to SMP-dextran during

incubation at 37° with purified swine kidney converting enzyme was followed by measuring the residual immunoreactive bradykinin in a radioimmunoassay.

Bradykinin coupled to SMP-dextran was hydrolyzed much slower by kininase II than uncoupled bradykinin. At the end of 1 h of incubation, about 80% of the kinin SMP-dextran conjugate was still immunologically active while native bradykinin was completely inactivated presumably by the removal of C-terminal dipeptide Phe-Arg (6).

The effects of bradykinin and bradykinin SMP-dextran on the rate of hydrolysis of Hip-Gly-Gly by converting enzyme were also studied. Bradykinin bound to SMP-dextran was less effective than native bradykinin in inhibiting the hydrolysis of Hip-Gly-Gly. For the same decrease in the rate of Hip-Gly-Gly hydrolysis, coupled bradykinin had to be present in higher concentration than free bradykinin. Oxidized-reduced dextran itself inhibited the hydrolysis of Hip-Gly-Gly, although this was only about 20% of the inhibition obtained with comparable concentrations of the bradykinin SMP-dextran complex.

Non-covalent Binding

To establish whether the activity of the kallikrein, aprotinin, SQ 21541, and bradykinin dextran complexes was due to covalently bound material and not to material adsorbed on the dextrans, control preparations were made in which the protein and the peptides were incubated with either non-activated dextran or oxidized-reduced dextran and the mixtures carried through the various purification steps. None of the control preparations had activity that could be attributed to adsorbed material.

DISCUSSION

These experiments have shown that components of the kallikrein-kinin system covalently coupled to high m.w. soluble dextran retain activity in

vitro. These include kallikrein, aprotinin, bradykinin, and the angiotensin I converting enzyme or kininase II inhibitor SQ 21541. They have biological importance and some are even used clinically.

For example

/ SQ 20881, a nonapeptide which is structurally related to the hexapeptide SQ 21541, has been used in clinical experiments to lower the elevated blood pressure of hypertensives. This compound can block the conversion of angiotensin I to II or the inactivation of bradykinin by inhibiting converting enzyme or kininase II (6).

The coupling of kallikrein to CNBr-dextran did not appear to affect its esterase activity since plotting the activity against the enzyme concentration yielded parallel curves for free and bound enzyme (Fig. 1). The kallikrein CNBr-dextran complex was found to retain approximately three-fourths the esterase activity of uncoupled kallikrein. This compares favorably with kallikrein bound to the hydroxysuccinimide ester of polyvinylpyrrolidone which had about one-fourth the activity of free kallikrein on BAEe (10).

Bradykinin coupled to SMP- or CNBr-dextran was still biologically and immunologically active. The immunological activity of either complex was always greater than its biological activity. Possibly there is more steric hindrance to the accommodation of the macromolecular kinin complexes at receptor sites than there is at antibody binding sites.

Bradykinin SMP-dextran was less susceptible than native bradykinin to hydrolysis by purified swine kidney converting enzyme or by the enzyme in human vascular endothelial cells grown in tissue culture (11). The mechanism of this protection could be due to the increased size of the molecule. The bradykinin SMP-dextran complex inhibited Hip-Gly-Gly hydrolysis by converting enzyme but less than free bradykinin did. This also indicates that the dextran bound peptide has a lower affinity for the enzyme than free bradykinin. The decreased in vitro

inactivation of the bradykinin-dextran complex by converting enzyme suggests that this complex may have a longer lasting activity in vivo than free bradykinin.

In summary binding various components of the kallikrein-kinin system to dextran resulted in soluble macromolecular complexes with a high percent incorporation. The complexes retained significant amounts of activity in vitro.

SUMMARY

Pig pancreatic kallikrein, aprotinin (Trasylol), SQ 21541, an angiotensin I converting enzyme or kininase II inhibitor, and bradykinin were each coupled covalently to soluble dextran (m.w. 500,000). Dextran had been activated either with cyanogen bromide or sodium meta-periodate. Of the reactants, 23 to 56% were bound to activated dextrans. The activities of the complexes were determined in vitro by spectrophotometric technique or radioimmunoassay and bio-assay. Depending on the mode of coupling and the test employed the soluble macromolecular complexes retained 6 to 92% of the in vitro activity of the native compound. Bradykinin coupled covalently to dextran was inactivated slower by converting enzyme than was free bradykinin.

REFERENCES

1. *Affinity Techniques Enzyme Purification: Part B, Methods in Enzymology* (Eds. W. B. Jakoby and M. Wilchek), Vol. XXXIV, Academic Press, New York 1974, 810 pp.
- 2.. H. Fritz, H. Schult, M. Hutzel, M. Wiedemann and E. Werle, Hoppe-Seyler's Z. Physiol. Chem. 348, 308 (1967).
3. H. Fritz, B. Brey, A. Schmal and E. Werle, Hoppe-Seyler's Z. Physiol. Chem. 350, 617 (1969).
4. T. Seki, H. Y. T. Yang, Y. Levin, T. A. Jenssen and E. G. Erdős, Adv. exp. Med. Biol. 8, 23 (1970).
5. T. Nakajima, T. Seki and E. G. Erdős, in *Protides of the Biological Fluids* (Ed. H. Peeters), Vol. 20, p. 323. Pergamon Press, New York (1973).
6. E. G. Erdős, Am. J. Med. 60, 749 (1976).
7. C. E. Ody, Y. Levin, E. G. Erdős and C. J. G. Robinson, Biochem. Pharmacol. In press.
8. R. Axen, J. Porath and S. Ernback, Nature 214, 1302 (1967).
9. T. L. Goodfriend and C. E. Ody, in *Methods of Hormone Radioimmunoassay* (Eds. B. M. Jaffe and H. R. Behrman) p. 439. Academic Press, New York (1974).

10. B. U. v. Specht, M. Wahl, H. J. Kolb and W. Brendel, Arch. Intern. Pharm. Ther. 213, 242 (1975).
11. A. Johnson and E. G. Erdős, J. Clin. Invest. 59, 684 (1977).

Footnotes:

*These studies have been supported in part by N.I.H., U.S.P.H.S. HL14187,
16320 and by ONR N00014 75 0807.

[†]Permanent address: The Weizmann Institute of Science, Department of Biophysics,
Rehovot, Israel

§To whom reprint requests should be addressed.

**These data were presented at the Spring Meeting of FASEB in Chicago Ill. (Fed.
Proc. 36: 1014, 1977)

Fig. 1. Effect of increasing the concentration of free and bound kallikrein on the rate of BAEe hydrolysis. 0—0 Purified pig pancreatic kallikrein. 0—0 Kallikrein bound to CNBr-dextran. Abscissa: Log concentration of kallikrein in μg per ml. Ordinate: Rate of hydrolysis of BAEe in O.D.₂₅₄ per min. (From Ody et al. Biochem. Pharmacol. In press)

Fig. 2. Inhibition of the enzymatic hydrolysis of BAEe by free and bound aprotinin (Trasylol). Highly purified pig pancreatic kallikrein was the source of enzyme. 0—0 Aprotinin. 0—0 Aprotinin bound to CNBr-dextran. Abscissa: Log concentration of aprotinin in ng per ml. Ordinate: Percent inhibition. (From Ody et al. Biochem. Pharmacol. In press)

TABLE 1

Activities of Soluble Dextran Complexes In Vitro

Substances Coupled	Yield (%)	Test	Activity (Unbound = 100%)	
Kallikrein ¹	56	Esterase	72	
Aprotinin ¹	35	Kallikrein inhibition	41	
SQ 21541 ²	38	Kininase II inhibition	24	
Bradykinin ^{1,2}	23 ¹ 45 ²	Rat uterus	$\frac{1}{6}$	$\frac{2}{29}$
		Guinea pig ileum	18	
		Kininase II inhibition	≈20	
		Radioimmunoassay	92	80
		Cleavage by kininase II	20	

1. Cyanogen bromide activated dextran.

2. Sodium meta-periodate activated dextran.

